Corteva remains a 'buy' as innovation offsets pressure on legacy products, BofA says

Impact · against what's priced in

Corteva's pivot to a pure-play crop protection business via the Vylor spin-off represents a structural shift in valuation, lowering its EBITDA multiple to 8.5x. While the long-term growth targets and analyst ratings are already baked in, the separation provides a clearer, more focused investment profile.

CTVA+0.40

No priced-in read yet